Fleury SA operates within the Medical laboratories sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Fleury SA with three other
pharmaceutical manufacturers in Latin America:
Instituto Hermes Pardini SA
sales of 1.49 billion Brazilian Reals [US$301.27 million]
of which 100%
was auxiliary diagnostic support services),
Genomma Lab Internacional Sab De Cv
(13.87 billion Mexican Pesos [US$681.58 million]
of which 100%
was PC), and
(4.09 billion Brazilian Reals [US$824.52 million]
During the first
quarter of 2021, sales at Fleury SA totalled
893.81 million Brazilian Reals.
an increase of 25.2%
from the 713.93 million Brazilian Reals in sales at the company during the first quarter of 2020.
There appears to be at least some degree of seasonality in the sales at Fleury SA: during 8 of the previous 9
years, sales were highest during the third quarter.
The exception to this was during 2020, when the
fourth quarter was the best quarter, accounting for
31% of sales (during that same year, the
third quarter accounted for 29% of sales).
During the year ended December of 2020, sales at
Fleury SA were 2.97 billion Brazilian Reals (US$599.23 million).
increase of 2.3%
versus 2019, when the company's sales were 2.91 billion Brazilian Reals.
This was the fifth consecutive year of sales increases at Fleury SA
(and since 2015, sales have increased a total of 57%).
Sales of Integrated Medicine saw an increase
that was more than double the company's growth rate: sales were up
15.3% in 2020, from
467.62 million Brazilian Reals to 538.93 million Brazilian Reals.
Not all segments of Fleury SA experienced an increase in sales in 2020:
sales of Diagnostic Medicine fell 0.2% to 2.43 billion Brazilian Reals.